{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:25:58Z","timestamp":1789608358058,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"crossref","award":["2096"],"award-info":[{"award-number":["2096"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.jneuroim.2012.05.004","type":"journal-article","created":{"date-parts":[[2012,6,23]],"date-time":"2012-06-23T03:31:14Z","timestamp":1340422274000},"page":"87-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran"],"prefix":"10.1016","volume":"250","author":[{"given":"Houshang","family":"Rafatpanah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdolrahim","family":"Rezaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mehdi","family":"Etemadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza Farid","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Khorram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Afsahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naghmeh","family":"Mokhber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Abbaszadegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Foroghipor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyman","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Amiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Azarpazhooh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Reza","family":"Azarpazhooh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jneuroim.2012.05.004_bb0005","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/13550280701397627","article-title":"Safety and efficacy of interferon-alpha in 167 patients with human T-cell lymphotropic virus type 1-associated myelopathy","volume":"13","author":"Arimura","year":"2007","journal-title":"J. Neurovirol."},{"issue":"3","key":"10.1016\/j.jneuroim.2012.05.004_bb0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ijc.2910300302","article-title":"The human type-C retrovirus, HTLV, in Blacks from the Caribbean region, and relationship to adult T-cell leukemia\/lymphoma","volume":"30","author":"Blattner","year":"1982","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.jneuroim.2012.05.004_bb0010","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/infdis\/147.3.406","article-title":"Epidemiology of human T-cell leukemia\/lymphoma virus","volume":"147","author":"Blattner","year":"1983","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.jneuroim.2012.05.004_bb0020","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ptj\/67.2.206","article-title":"Interrater reliability of a modified Ashworth scale of muscle spasticity","volume":"67","author":"Bohannon","year":"1987","journal-title":"Phys. Ther."},{"issue":"5","key":"10.1016\/j.jneuroim.2012.05.004_bb0025","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/aid.1993.9.381","article-title":"An HTLV-I vaccine: why, how, for whom?","volume":"9","author":"de The","year":"1993","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2012.05.004_bb0035","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0165-5728(03)00219-4","article-title":"Interferon-alpha significantly reduces cerebrospinal fluid CD4 cell subsets in HAM\/TSP","volume":"141","author":"Feng","year":"2003","journal-title":"J. Neuroimmunol."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2012.05.004_bb0030","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jneuroim.2004.02.007","article-title":"Th1\/Th2 balance and HTLV-I proviral load in HAM\/TSP patients treated with interferon-alpha","volume":"151","author":"Feng","year":"2004","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.jneuroim.2012.05.004_bb0040","first-page":"205","article-title":"Successful 2-year therapy with systemic interferon-alpha for HTLV-I associated myelopathy","volume":"162","author":"Gazzola","year":"1999","journal-title":"J. Neurol. Sci."},{"issue":"8452","key":"10.1016\/j.jneuroim.2012.05.004_bb0045","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(85)92734-5","article-title":"Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis","volume":"2","author":"Gessain","year":"1985","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jneuroim.2012.05.004_bb0050","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ijc.2910290606","article-title":"Antibodies to adult T-cell leukemia-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: a nation-wide sero-epidemiologic study","volume":"29","author":"Hinuma","year":"1982","journal-title":"Int. J. Cancer"},{"issue":"39","key":"10.1016\/j.jneuroim.2012.05.004_bb0055","first-page":"242","article-title":"Effect of alpha-interferon treatment on HTLV-1 associated myelopathy (HAM)","author":"Izumo","year":"1988","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jneuroim.2012.05.004_bb0060","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1212\/WNL.46.4.1016","article-title":"Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial","volume":"46","author":"Izumo","year":"1996","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jneuroim.2012.05.004_bb0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jviromet.2004.06.007","article-title":"Comparison of three current viral load assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma","volume":"121","author":"Katsoulidou","year":"2004","journal-title":"J. Virol. Methods"},{"issue":"2","key":"10.1016\/j.jneuroim.2012.05.004_bb0070","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/10428190601071717","article-title":"Zidovudine and interferon-alpha treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran","volume":"48","author":"Kchour","year":"2007","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.jneuroim.2012.05.004_bb0075","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ijc.2910440307","article-title":"A survey of the human T-cell lymphotropic virus type I (HTLV-I) in south-western Colombia","volume":"44","author":"Maloney","year":"1989","journal-title":"Int. J. Cancer"},{"issue":"8620","key":"10.1016\/j.jneuroim.2012.05.004_bb0080","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(88)90525-9","article-title":"Plasmapheresis in treatment of human T-lymphotropic virus type-I associated myelopathy","volume":"2","author":"Matsuo","year":"1988","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jneuroim.2012.05.004_bb0085","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/13550289609146899","article-title":"Therapeutic trials in 200 patients with HTLV-I-associated myelopathy\/tropical spastic paraparesis","volume":"2","author":"Nakagawa","year":"1996","journal-title":"J. Neurovirol."},{"issue":"4","key":"10.1016\/j.jneuroim.2012.05.004_bb0090","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2169\/internalmedicine1962.29.362","article-title":"The efficacy of interferon-alpha treatment in human T-lymphotropic virus type-I-associated myelopathy","volume":"29","author":"Nakamura","year":"1990","journal-title":"Jpn. J. Med."},{"key":"10.1016\/j.jneuroim.2012.05.004_bb0100","series-title":"Review of WHO Kagoshima Meeting and Diagnostic Guidelines for HAM\/TSP","author":"Osame","year":"1990"},{"issue":"8488","key":"10.1016\/j.jneuroim.2012.05.004_bb0105","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0140-6736(86)91298-5","article-title":"HTLV-I associated myelopathy, a new clinical entity","volume":"1","author":"Osame","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2012.05.004_bb0095","first-page":"271","article-title":"HTLV-1-associated myelopathy (HAM): treatment trials, retrospective survey, and clinical and laboratory findings","volume":"3","author":"Osame","year":"1990","journal-title":"Hematol. Rev."},{"issue":"2","key":"10.1016\/j.jneuroim.2012.05.004_bb0115","first-page":"94","article-title":"Association between HLA-DRB1*01 and HLA-Cw*08 and outcome following HTLV-I infection","volume":"4","author":"Rafatpanah","year":"2007","journal-title":"Iran J. Immunol."},{"key":"10.1016\/j.jneuroim.2012.05.004_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2011.07.004","article-title":"High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey","author":"Rafatpanah","year":"2011","journal-title":"J. Clin. Virol."},{"issue":"3","key":"10.1016\/j.jneuroim.2012.05.004_bb0120","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/oxfordjournals.aje.a114828","article-title":"Human T-cell lymphotropic virus type I (HTLV-I) seroepidemiology and risk factors in metropolitan Panama","volume":"127","author":"Reeves","year":"1988","journal-title":"Am. J. Epidemiol."},{"issue":"Pt 3","key":"10.1016\/j.jneuroim.2012.05.004_bb0125","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1099\/vir.0.80509-0","article-title":"Differences in viral and host genetic risk factors for development of human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy\/tropical spastic paraparesis between Iranian and Japanese HTLV-1-infected individuals","volume":"86","author":"Sabouri","year":"2005","journal-title":"J. Gen. Virol."},{"issue":"1","key":"10.1016\/j.jneuroim.2012.05.004_bb0130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1086\/380101","article-title":"Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy\/tropical spastic paraparesis","volume":"189","author":"Saito","year":"2004","journal-title":"J. Infect. Dis."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2012.05.004_bb0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jns.2006.02.004","article-title":"Flow cytometry evaluation of the T-cell receptor V beta repertoire among human T-cell lymphotropic virus type-1 (HTLV-1) infected individuals: effect of interferon alpha therapy in HTLV-1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP)","volume":"246","author":"Saito","year":"2006","journal-title":"J. Neurol. Sci."},{"issue":"4669","key":"10.1016\/j.jneuroim.2012.05.004_bb0140","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1126\/science.6089348","article-title":"Human T-cell leukemia virus (HTLV-I) antibodies in Africa","volume":"225","author":"Saxinger","year":"1984","journal-title":"Science"},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2012.05.004_bb0145","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1386-6532(00)00152-9","article-title":"Performance characteristics of quantification assays for human immunodeficiency virus type 1 RNA","volume":"20","author":"Schmitt","year":"2001","journal-title":"J. Clin. Virol."},{"issue":"10","key":"10.1016\/j.jneuroim.2012.05.004_bb0150","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1212\/WNL.43.10.2125","article-title":"High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy","volume":"43","author":"Sheremata","year":"1993","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jneuroim.2012.05.004_bb0155","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0022-510X(91)90256-7","article-title":"Interferon-alpha treatment in HTLV-I-associated myelopathy. Studies of clinical and immunological aspects","volume":"106","author":"Shibayama","year":"1991","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.jneuroim.2012.05.004_bb0160","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/1097-0142(19870315)59:6<1059::AID-CNCR2820590602>3.0.CO;2-M","article-title":"Recombinant interferon beta and gamma in the treatment of adult T-cell leukemia","volume":"59","author":"Tamura","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.jneuroim.2012.05.004_bb0165","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1742-4690-3-63","article-title":"Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial","volume":"3","author":"Taylor","year":"2006","journal-title":"Retrovirology"},{"issue":"2","key":"10.1016\/j.jneuroim.2012.05.004_bb0170","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0022-510X(96)05319-1","article-title":"Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy\/tropical spastic paraparesis: a combined clinical, virological and immunological study","volume":"147","author":"Yamasaki","year":"1997","journal-title":"J. Neurol. Sci."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572812001580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572812001580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:20:25Z","timestamp":1759047625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572812001580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":34,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0165572812001580"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2012.05.004","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2012.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}